| Management target | Revenue FY30 |
|---|
| Revenue growth | 16.6% YoY in FY26. |
|---|---|
| Margins | EBITDA margin expansion from 18.5% to 19.4% over FY24-FY26. |
| Demand visibility | Strong domestic chronic demand and Europe/Canada pipeline. |
| Management confidence | High; citing 'stronger returns' and 'diversified growth platform'. |
Growth
FY26 revenue grew 16.6% YoY; PAT surged 33% YoY. EBITDA margins improved to 19.4% (+90 bps).
Outlook
Targets FY26-FY30 growth via obesity/oncology assets and R&D platforms like Biologics and ADCs.
Risks
Regulatory changes, supply chain challenges, and currency fluctuations in international markets.
Last quarter's promises, checked
Delivered
- Revenue growth low-to-mid-teens → Delivered 22.8% (= BEAT)
- Domestic growth return to double-digits → Delivered 10.2% (= BEAT)
- EBITDA margin expansion 70-100 bps → Delivered 19.7%, up 50 bps YoY but 120 bps vs FY24 (= BEAT)
Partly delivered
- Gross margin target 60% → Delivered 58.4% due to product mix (= PARTIAL)
Investor Presentation filed with BSE, NSE: EMCURE. Summary written with AI assistance from the document.
Emcure Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,922.40
- Market cap
- ₹36,470 Cr
- Revenue (annual)
- ₹9,204 Cr
- Net profit (annual)
- ₹924.4 Cr
- P/E (TTM)
- 36.1×Sector 47.4×
- Promoter holding
- 77.83%-0.04% QoQ
- FII holding
- 4.87%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Emcure Pharmaceuticals Ltd
All →Emcure Pharmaceuticals Annual General Meeting
Emcure Pharmaceuticals held its 45th Annual General Meeting on September 21, 2026. The meeting transacted ordinary and special business, including the approval of a final dividend.
Emcure Pharmaceuticals Employee Stock Options
Emcure Pharmaceuticals allotted 11,400 equity shares to employees following the exercise of vested options under the ESOP scheme. This increases the company's total issued share capital.
Emcure Pharmaceuticals Credit Rating
Emcure Pharmaceuticals received a credit rating reaffirmation from CARE Ratings for its existing bank facilities. The company maintains its stable outlook and financial profile.
Emcure Pharmaceuticals Other Announcement
Emcure Pharmaceuticals has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 as part of its Annual Report.
Emcure Pharmaceuticals Annual General Meeting
Emcure Pharmaceuticals has issued a notice for its 45th Annual General Meeting to be held on September 21, 2026. The meeting will address financial statements, dividends, and directorship appointments.
Emcure Pharmaceuticals Annual Report
Emcure Pharmaceuticals has filed its Annual Report for the financial year 2025-26 and the notice for its 45th Annual General Meeting.